financetom
Business
financetom
/
Business
/
Coach Parent Warns Of Tariff Pressure Despite Strong Performance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Coach Parent Warns Of Tariff Pressure Despite Strong Performance
Aug 14, 2025 6:17 AM

Tapestry, Inc. ( TPR ) stock tumbled in premarket trading Thursday despite topping Wall Street forecasts for the fourth quarter, fueled by double-digit revenue growth at its flagship Coach brand.

The parent of Coach and Kate Spade posted adjusted earnings of $1.04 per share, ahead of the $1.02 consensus, on revenue of $1.72 billion, up 8% year-over-year and above expectations.

Coach saw strong handbag revenue growth, driven by a mid-teens AUR gain for the quarter and a low-double-digit gain for the year. This reflects compelling innovation and broad-based traction across its leather goods offerings.

Also Read: Starbucks Under 4 Minutes: CEO Brian Niccol’s New ‘Green Apron’ Plan Aims To End Long Waits

Tapestry’s overall revenue growth was led by a 14% (+13% constant currency) gain at the Coach Brand with $1.425 billion in revenues. Kate Spade revenues fell 13% to $252.6 million.

Gross profit rose to $1.32 billion from $1.19 billion a year ago. Gross margin increased to 76.3% from 74.9%, driven by about 200 basis points of operational improvements, partly offset by a currency headwind of over 50 basis points.

Cash, equivalents, and short-term investments totaled $1.12 billion, while total borrowings stood at $2.39 billion. This resulted in net debt of $1.27 billion.

Inventory was $861 million, as expected, which excluded $92 million of Stuart Weitzman inventory classified as Assets held for sale.

Dividend

The firm approved a 14% increase to the company’s dividend, with a quarterly cash dividend of 40 cents per common share payable on September 22 to shareholders of record as of the close of business on September 5.

“We achieved bold targets we set three years ago in a dynamic landscape, delivering over $5 in adjusted earnings per share and returning more than $3 billion cumulatively to shareholders,” said CEO Joanne Crevoiserat

Outlook

For fiscal 2026, Tapestry expects revenue to approach $7.2 billion compared to the $6.96 billion estimate, reflecting low-single-digit growth from last year.

Excluding the planned divestiture of Stuart Weitzman, pro-forma sales are projected to rise at a mid-single-digit pace on both a nominal and constant-currency basis, with foreign exchange providing an 80-basis-point boost.

Operating margin is forecast to improve by more than 250 basis points, though this will be largely offset by an estimated 230-basis-point drag from incremental tariffs and duties, a $160 million impact tied to policy changes, sell-through timing, and mitigation efforts. The company aims to fully offset these costs over time.

Management projects net interest expense of about $65 million, an effective tax rate of roughly 18%, and a weighted average diluted share count near 213 million. Adjusted EPS is guided at $5.30-$5.45, up 4%-7% year-over-year, despite more than 60 cents in negative tariff and duty effects. Adjusted free cash flow is expected to approach $1.3 billion.

Price Action: TPR shares are trading lower by 12.36% to $99.50 premarket at last check Thursday.

Read Next:

Dow Surges More Than 400 Points: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone

Image via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FOCUS-FDA upheaval pushes some biotech firms to plan early trials out of US
FOCUS-FDA upheaval pushes some biotech firms to plan early trials out of US
May 26, 2025
* Biotechs fear changes at FDA could slow U.S. drug development * Some firms looking at 'Europe first' for testing experimental drugs * FDA considered global gold standard for drug regulation By Maggie Fick LONDON, May 14 (Reuters) - Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry grows that layoffs...
eToro Prices Upsized IPO Above Indicative Range
eToro Prices Upsized IPO Above Indicative Range
May 26, 2025
04:01 AM EDT, 05/14/2025 (MT Newswires) -- eToro Group said late Tuesday it priced its initial public offering of about 11.9 million class A common shares at $52 per share, upsized from 10 million shares. The company was targeting an indicative range of $46 to $50 per share. About 6 million shares in the offering will be sold by the...
Workers strike in protest against job cuts at Ford Germany
Workers strike in protest against job cuts at Ford Germany
May 26, 2025
COLOGNE (Reuters) -Workers at Ford's two car plants in the German city of Cologne went on strike on Wednesday, protesting thousands of planned job cuts across the U.S. automaker's European operations. The cuts at Ford reflect a broader shake-up in the car sector as companies like Volkswagen, Nissan and General Motors axe jobs in response to new competition from China,...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved